Skip to main
NVAX

Novavax (NVAX) Stock Forecast & Price Target

Novavax (NVAX) Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 38%
Buy 13%
Hold 13%
Sell 25%
Strong Sell 13%

Bulls say

Novavax is well-positioned for growth due to its unique vaccine technology and impressive pipeline of high-value assets. The positive outlook for Novavax is further supported by its partnerships with other companies to drive value creation and its potential to address both known and emerging diseases. The recent survey results project a declining COVID-19 vaccine market in the US, which could lead to increased demand for Novavax's vaccine candidates. Furthermore, the positive results from the Sanofi COMPARE study and the potential differentiated tolerability profile of Nuvaxovid may give Novavax a competitive edge in the market.

Bears say

Novavax is a biotechnology company with several potential opportunities, including a commercial partnership with Sanofi that could provide mid-term growth, and internal pipeline candidates that could add value in the long term. However, there are significant challenges, such as the uncertain outlook for COVID-19 vaccines and the commercial viability of a flu/COVID-19 combo vaccine, which could impede the company's success. Additionally, with competition from established vaccine manufacturers and the company's emphasis on its Matrix-M adjuvant, which has yet to show significant impact, there are concerns about the company's ability to gain market share and generate sustainable profits in the near term.

Novavax (NVAX) has been analyzed by 8 analysts, with a consensus rating of Hold. 38% of analysts recommend a Strong Buy, 13% recommend Buy, 13% suggest Holding, 25% advise Selling, and 13% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novavax (NVAX) Forecast

Analysts have given Novavax (NVAX) a Hold based on their latest research and market trends.

According to 8 analysts, Novavax (NVAX) has a Hold consensus rating as of Jun 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novavax (NVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.